Drugs / TdaP vaccine SSI
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01033877 | Jan → Aug 2010 | — | Statens Serum Institut | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TdaP vaccine SSI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01033877 ↗ |
| Known as | TdaP vaccine | “The clinical trial is a phase III, double-blind, randomised, controlled, multi-centre, clinical trial, on the immunogenicity and safety of TdaP vaccine in comparison to Td...” NCT01033877 ↗ |
| Modality | Vaccine | “The monocomponent acellular pertussis vaccine (aP) in the TdaP vaccine was immunogenic in adults” PMID 22776216 ↗ Jul 2012 |